In this article the topic of Radotinib will be addressed from a broad and enriching perspective. The relevance of Radotinib in different contexts will be analyzed, as well as its impact on current society. Throughout the text, different approaches and points of view on Radotinib will be explored, with the aim of providing a comprehensive and enriching vision on this topic. In addition, relevant data and illustrative examples will be presented that will allow the reader to gain greater knowledge and understanding about Radotinib.
![]() | |
Clinical data | |
---|---|
Trade names | Supect |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H21F3N8O |
Molar mass | 530.515 g·mol−1 |
3D model (JSmol) | |
| |
|
Radotinib (INN; trade name Supect), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.
Radotinib is being developed by Ilyang Pharmaceutical Co., Ltd of South Korea and is co-marketed by Daewoong Pharmaceutical Co. Ltd, in South Korea. Radotinib completed a multi-national Phase II clinical trial study in 2012 and in August 2011, Ilyang initiated a Phase III, multinational, multi-center, open-label, randomized study for first-line indication. Its mechanism of action involves inhibition of the Bcr-Abl tyrosine kinase and of platelet-derived growth factor receptor (PDGFR).